Orion Portfolio Solutions LLC increased its holdings in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 26.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The company owned 68,121 shares of the medical device company after acquiring an additional 14,360 shares during the quarter. Orion Portfolio Solutions LLC owned about 0.14% of AtriCure worth $2,072,000, according to its most recent SEC filing.

A number of other institutional investors also made changes to their positions in the company. State of New Jersey Common Pension Fund D increased its position in AtriCure by 31.1% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 68,188 shares of the medical device company’s stock worth $2,434,000 after purchasing an additional 16,168 shares during the period. Knights of Columbus Asset Advisors LLC increased its holdings in AtriCure by 165.8% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 123,540 shares of the medical device company’s stock worth $4,409,000 after purchasing an additional 77,055 shares during the period. Bridger Management LLC acquired a new position in AtriCure in the fourth quarter worth approximately $3,109,000. Wellington Management Group LLP increased its stake in AtriCure by 7.8% in the 4th quarter. Wellington Management Group LLP now owns 1,329,457 shares of the medical device company’s stock worth $47,448,000 after acquiring an additional 95,824 shares during the period. Finally, Panagora Asset Management Inc. increased its stake in AtriCure by 38.0% in the 4th quarter. Panagora Asset Management Inc. now owns 229,197 shares of the medical device company’s stock worth $8,180,000 after acquiring an additional 63,079 shares during the period. 99.11% of the stock is held by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ATRC shares. Oppenheimer raised AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price target on the stock in a research report on Tuesday, April 23rd. JPMorgan Chase & Co. lowered their price target on AtriCure from $42.00 to $34.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com lowered AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. Canaccord Genuity Group lowered their price target on shares of AtriCure from $57.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price target on shares of AtriCure in a research report on Monday, July 8th. One analyst has rated the stock with a “sell” rating and seven have issued a “buy” rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.78.

Get our latest stock analysis on ATRC

AtriCure trades down 2.0%

Shares of NASDAQ ATRC opened Friday at $24.17. The stock’s 50-day moving average is $22.56 and its 200-day moving average is $27.65. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $59.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 4.00.

AtriCure (NASDAQ:ATRC – Get Free Report) last released its earnings results on Wednesday, May 01. The medical device company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). AtriCure had a negative net margin of 8.98% and a negative return on equity of 7.85%. The company had revenue of $108.90 million during the quarter, compared to the consensus estimate of $106.86 million. During the same period in the prior year, the company earned ($0.23) EPS. AtriCure’s quarterly revenue increased 16.5% compared to the same quarter last year. Analysts as a group predict that AtriCure, Inc. will post -0.75 EPS for the current fiscal year.

Insider activity at AtriCure

In other AtriCure news, insider Salvatore Privitera bought 5,000 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were purchased at an average price of $22.25 per share, for a total transaction of $111,250.00. Following the completion of the purchase, the insider now directly owns 103,290 shares of the company’s stock, valued at $2,298,202.50. The acquisition was disclosed in a filing with the SEC, available at this link. In other AtriCure news, insider Salvatore Privitera bought 5,000 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were purchased for an average price of $22.25 per share, for a total value of $111,250.00. Following the completion of the purchase, the insider now owns 103,290 shares of the company’s stock, valued at $2,298,202.50. The purchase was disclosed in a filing with the SEC, which can be accessed at this link. Also, insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction dated Wednesday, May 1. The stock was sold at an average price of $24.09, for a total transaction of $36,135.00. Following the completion of the transaction, the insider now directly owns 71,284 shares of the company’s stock, valued at approximately $1,717,231.56. The disclosure for this sale can be found here. 3.20% of the company’s stock is currently held by insiders.

About AtriCure

(Free Report)

AtriCure, Inc. develops, manufactures and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporary blocking of pain through peripheral nerve ablation at medical centers in the United States, Europe, Asia Pacific and internationally. The company offers Isolator Synergy Clamps, single-use, disposable radiofrequency products; multi-function pens and linear ablation devices, such as the MAX Pen device, which enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing and pacing, and ablate cardiac tissue with the same device; and the Coolrail device, which allows users to create longer linear ablation lines.

Also see

Get news and reviews for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.